the future of allergy attacks

Revolutionising the emergency treatment of anaphylaxis, ZiBiPen proves that life-saving treatment can be as affordable as it is effective.  

a revolutionary auto-injector


Anaphylaxis is a severe allergic reaction when a patient is exposed to an antigen to which they have become hyperallergic. Exposure to these antigens results in the release of mediators from mast cells in the body, causing inflammation of critical organ systems. 

This leads to abdominal cramping, heart palpitations, vomiting, swelling of the face, and breathing problems. Without immediate treatment, it can lead to patient mortality within 15 minutes.

To increase the probability of patient survival, a dose of adrenaline must be administered. There are several routes of administration, but the use of an Adrenaline Auto-Injector is the safest, quickest and most efficient route. 

The continuous annual purchase of an adrenaline auto-injector due to expiration and non-use is a major issue for patients across the globe. Furthermore, current devices do not effectively cater to variation in patient weight and body type.


Adrenaline auto-injectors treat life-threatening severe allergic reactions – buying precious time to get to the hospital. 

ZiBiPen delivers its dose in the form of a reloadable cartridge at a fraction of the cost of the dominant device on the market.

Estimated Time of Arrival

2022 – The ZiBiPen is in the second phase of development to make sure the device is both effective and safe for use by all ages and body types.

quick facts

Industry Context

More than 89% of Pharmacists want an alternative to the current device in the market, because patients can’t afford it.


We are in negotiations with a market leading pharmaceutical company to supply the prefilled adrenaline syringes.


We are in active negotiations with various distributors to get the product into your hands.

Proof of Concept

We have a fully functional device that has been pre-clinically tested against the current market leader.

Research and Development

The device was developed at the University of Cape Town by a team of experienced engineers and clinicians.


The ZiBiPen is the only reloadable adrenaline autoinjector and has customisable depth of injection to improve injection effectiveness.